FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency initiates advance notice of proposed rulemaking to determine whether an active drug ingredient can be marketed both Rx and OTC for the same indication.